• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Antiplatelet agents for chronic kidney disease
CONCLUSIONS: Antiplatelet agents probably reduced myocardial infarction and increased major bleeding, but do not appear to reduce all-cause and cardiovascular death among people with CKD and those treated with dialysis. The treatment effects of antiplatelet agents compared with each other are uncertain.PMID:35224730 | DOI:10.1002/14651858.CD008834.pub4
Source: Cochrane Database of Systematic Reviews - February 28, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Valeria M Saglimbene Marinella Ruospo Mona Razavian Jonathan C Craig Meg J Jardine Angela C Webster Giovanni Fm Strippoli Source Type: research

Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice
Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the accumulation of glycolipids including globotriaosylceramide in cells of various tissues resulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma and recurrent episodes of neuropathic pain in the extremities occurring during childhood or adolescence. Most affected patients also exhibit a decreased ability to sweat. Later in life, FD results in left ventricular hypertrophy, proteinuria, renal failure and stroke. These later disease manifestations are non-specific and also common in diabetes, hyp...
Source: Nephrology Dialysis Transplantation - March 5, 2013 Category: Urology & Nephrology Authors: Terryn, W., Cochat, P., Froissart, R., Ortiz, A., Pirson, Y., Poppe, B., Serra, A., Van Biesen, W., Vanholder, R., Wanner, C. Tags: NDT PERSPECTIVES Source Type: research

Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients
End-stage renal disease (ESRD) patients exhibit an increased risk of bleeding compared with non-chronic kidney disease (CKD) patients due to uraemic platelet dysfunction, altered vessel architecture and other factors. This renders any long-term oral anticoagulation potentially difficult. While there is little doubt that ESRD patients with recurrent thromboembolism or a mechanical cardiac valve should receive vitamin K antagonists (coumarins), the use of coumarins in ESRD patients with atrial fibrillation is a matter of debate. In non-CKD patients, current guidelines strongly recommend the use of oral anticoagulants for str...
Source: Nephrology Dialysis Transplantation - March 5, 2013 Category: Urology & Nephrology Authors: Kruger, T., Brandenburg, V., Schlieper, G., Marx, N., Floege, J. Tags: CLINICAL SCIENCE AND OUTCOME RESEARCH IN NEPHROLOGY Source Type: research

Kidney disease and cognitive function.
Abstract We provide a brief review of research on chronic kidney disease and cognitive performance, including dementia. We touch briefly on the literature relating end-stage-renal disease to cognitive function, but focus on studies of modest and moderate forms of chronic kidney disease (CKD) that precede dialysis and transplantation. We summarize previous reviews dealing with case control studies of patients but more fully examine community-based studies with large samples and necessary controls for demographic risk factors, cardiovascular variables, and other confounds such as depression. In addition we suggest p...
Source: Contributions to Nephrology - May 26, 2013 Category: Urology & Nephrology Authors: Elias MF, Dore GA, Davey A Tags: Contrib Nephrol Source Type: research

Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study
Conclusions: In a cohort of participants with CKD, low serum bicarbonate level was an independent risk factor for kidney disease progression, particularly for participants with preserved kidney function. The risk of heart failure was higher at the upper extreme of serum bicarbonate levels. There was no association between serum bicarbonate level and all-cause mortality or atherosclerotic events.
Source: American Journal of Kidney Diseases - March 13, 2013 Category: Urology & Nephrology Authors: Mirela Dobre, Wei Yang, Jing Chen, Paul Drawz, L. Lee Hamm, Edward Horwitz, Thomas Hostetter, Bernard Jaar, Claudia M. Lora, Lisa Nessel, Akinlolu Ojo, Julia Scialla, Susan Steigerwalt, Valerie Teal, Myles Wolf, Mahboob Rahman, CRIC Investigators Tags: Pathogenesis and Treatment of Kidney Disease Source Type: research

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research

Fp332 * risk factors for stroke in people with end-stage kidney disease: a cohort study of 10,745 people
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Masson, P., Kotwal, S., Kelly, P. J., Craig, J. C., Lindley, R. I., Gallagher, M., Cass, A., Webster, A. C. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 1 Source Type: research

Sp372 * increased risk of ischemic stroke in patients with chronic kidney disease after recurrent dysnatremia: a nationwide population based cohort study in taiwan
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Chung, M.-C., Yu, T.-M., Wu, M.-J., Chang, C.-H., Muo, C.-H., Shu, K.-H., Chen, H.-W., Chung, C.-J. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 2 Source Type: research

Sp378 * does the presence of chronic kidney disease influence haemorrhagic stroke outcomes?
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Thomas, P., Carr, P., Sandler, D., Baharani, J. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 2 Source Type: research

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
CONCLUSIONS: We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD. PMID: 26671531 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 16, 2015 Category: Journals (General) Authors: Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G Tags: Cochrane Database Syst Rev Source Type: research

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Background Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD. Methods The STOP-ACEi trial (tri...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., El Nahas, M. Tags: Chronic Kidney Disease Source Type: research

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
Abstract Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as infections, sensitization impeding transplantation, and secondary iron overload. However, even in the initial studies, untoward effects were noted in patients receiving ESAs, including worsening hypertension, seizure...
Source: Clinical Drug Investigation - February 19, 2016 Category: Drugs & Pharmacology Source Type: research

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
Conclusion In Asian type 2 diabetic patients with chronic kidney disease and heavy proteinuria, reduction of SBP ≤ 130 mmHg was associated with greater renoprotection than cardioprotection. However, our results emphasize the need to individualize BP targets in type 2 diabetes.
Source: Nephrology Dialysis Transplantation - February 22, 2016 Category: Urology & Nephrology Authors: Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., Chan, J. C. N. Tags: Chronic Kidney Disease Source Type: research

APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans
Conclusions Greater numbers of APOL1 G1/G2 risk alleles were associated with higher small HDL particle concentrations in African Americans. These results may suggest novel areas of investigation to uncover reasons for the association between APOL1 risk variants with adverse outcomes in African Americans.
Source: Nephrology Dialysis Transplantation - March 22, 2016 Category: Urology & Nephrology Authors: Gutierrez, O. M., Judd, S. E., Irvin, M. R., Zhi, D., Limdi, N., Palmer, N. D., Rich, S. S., Sale, M. M., Freedman, B. I. Tags: Chronic Kidney Disease Source Type: research

Defining end-stage renal disease in clinical trials: a framework for adjudication
Unlike definition of stroke and myocardial infarction, there is no uniformly agreed upon definition to adjudicate end-stage renal disease (ESRD). ESRD remains the most unambiguous and clinically relevant end point for clinical trialists, regulators, payers and patients with chronic kidney disease. The prescription of dialysis to patients with advanced chronic kidney disease is subjective and great variations exist among physicians and countries. Given the difficulties in diagnosing ESRD, the presence of estimated GFR <15 mL/min/1.7 3m2 itself has been suggested as an end point. However, this definition is still a surrog...
Source: Nephrology Dialysis Transplantation - May 22, 2016 Category: Urology & Nephrology Authors: Agarwal, R. Tags: IDEAS, CONJECTURES AND REFUTATIONS Source Type: research

Pages: 1  2  3  4